COMPLETED

Effects of a Wellbeing Intervention on Inflammation Through Reward and Threat Processes

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to evaluate how savoring influences reward and threat processes and downstream inflammation. Savoring is designed to enhance positive affect, which may blunt stress responses and reduce downstream inflammation. The investigators aim to examine changes in the brain following the savoring intervention. The investigators are particularly interested in changes in brain activity that are correlated with changes in inflammation-related markers in the blood. In this single-armed pilot trial, the investigators will assess how savoring alters reactivity to rewarding and threatening experiences, and then examine related changes in downstream inflammation. The investigators intend to recruit 20 undergraduate students to complete a 7-week standardized savoring intervention. Participants will complete brain scans, daily diaries, questionnaires, a behavioral task, and blood collection at pre- and post-intervention assessments.

Official Title

Effects of a Wellbeing Intervention on Inflammation Through Reward and Threat Processes

Quick Facts

Study Start:2024-02-07

Study Completion:2025-05-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT06294145

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 25 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Moderate to moderately severe depression indicated by a PHQ-8 score between 9 and 20 * Low positive affect indicated by a PANAS score of less than 24 * No anxiety to moderate anxiety indicated by a GAD-7 score of less than 15 * 18 to 25 years old * English speaking * Willing to refrain from starting other psychosocial/pharmacological treatments until study completion	* MRI contraindications (left-handedness, claustrophobia, colorblindness, pregnancy, metal implants, and BMI above 35) * Presence of disease that may influence inflammation (e.g. asthma requiring inhaler, autoimmune or inflammatory diseases, gum disease, sleep disorder, eating disorder) * Presence of serious medical conditions (e.g. anemia, cancer (current or history), diabetes, endocrine disorder, fibromyalgia, heart problems) * Presence of disease that may impact patterns of neural activity (e.g. Attention Deficit/Hyperactivity Disorder, bipolar disorder, schizophrenia, head trauma, epilepsy, problems with drugs or alcohol) * Use of medications that may influence inflammation in last 6 months * Bupropion, dopaminergic or neuroleptic medications in last 6 months, consistent with other studies that investigate anhedonia, given their potential influence upon reward processing * Current use of heterocyclics and SSRIs if not stabilized for at least 3 months * History of regular (5-7 times per week) drug use (marijuana, cocaine, stimulant use before age of 15) * Current nicotine use (more than 11 cigarettes a week or nicotine equivalent) * Prior or current behavioral activation psychotherapy * Concurrent psychotherapy

Inclusion Criteria

Exclusion Criteria

* Moderate to moderately severe depression indicated by a PHQ-8 score between 9 and 20
* Low positive affect indicated by a PANAS score of less than 24
* No anxiety to moderate anxiety indicated by a GAD-7 score of less than 15
* 18 to 25 years old
* English speaking
* Willing to refrain from starting other psychosocial/pharmacological treatments until study completion

* MRI contraindications (left-handedness, claustrophobia, colorblindness, pregnancy, metal implants, and BMI above 35)
* Presence of disease that may influence inflammation (e.g. asthma requiring inhaler, autoimmune or inflammatory diseases, gum disease, sleep disorder, eating disorder)
* Presence of serious medical conditions (e.g. anemia, cancer (current or history), diabetes, endocrine disorder, fibromyalgia, heart problems)
* Presence of disease that may impact patterns of neural activity (e.g. Attention Deficit/Hyperactivity Disorder, bipolar disorder, schizophrenia, head trauma, epilepsy, problems with drugs or alcohol)
* Use of medications that may influence inflammation in last 6 months
* Bupropion, dopaminergic or neuroleptic medications in last 6 months, consistent with other studies that investigate anhedonia, given their potential influence upon reward processing
* Current use of heterocyclics and SSRIs if not stabilized for at least 3 months
* History of regular (5-7 times per week) drug use (marijuana, cocaine, stimulant use before age of 15)
* Current nicotine use (more than 11 cigarettes a week or nicotine equivalent)
* Prior or current behavioral activation psychotherapy
* Concurrent psychotherapy

Contacts and Locations

Study Locations (Sites)

University of California, Los Angeles

Los Angeles, California, 90095

United States

Collaborators and Investigators

Sponsor: University of California, Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-07

Study Completion Date2025-05-01

Study Record Updates

Study Start Date2024-02-07

Study Completion Date2025-05-01

Terms related to this study

Additional Relevant MeSH Terms

Low Positive Affect